



## COVID-19 - VOGO participation in the development, production and distribution of a rapid saliva-based screening test

**VOGO (ISIN: FR0011532225 - Ticker: ALVGO) is announcing that it is collaborating with scientists from the CNRS (French National Center for Scientific Research) laboratory Sys2Diag, and with biotechnology company SkillCell for providing a rapid saliva-based screening test, if the results of the clinical trial are conclusive.**

Faced with the current health crisis, it has been established that widespread rapid testing of populations would have a decisive impact. The EasyCov test has all the qualities to be able to meet this challenge.

Since April 11th, a clinical trial has been promoted by the Montpellier University Hospital with SkillCell and scientists from the CNRS laboratory Sys2Diag. If the results of the clinical trial are conclusive, an efficient and reliable development, production and distribution chain for widespread rapid testing of medical personnel could be ready as early as May.

All the details of the clinical trial project are developed in the press release dated April 10, 2020 available on the CNRS website <sup>(1)</sup>.

Development of a version of Easycov for the general public is in progress. As an expert in developing audio and video communication systems for use where there are large groups of people (sports venues for example) and operating cutting-edge image, network and Artificial Intelligence (AI) technology, VOGO has been selected to develop and launch the digital tool that will automate results analysis via colorimetric reading of the EasyCov test, which would be required for widespread screening of the population.

VOGO has already begun developing the technological tool (a smartphone app) that will provide this automation.

In addition to this project, on which 25% of the company's R&D teams are working, VOGO remains focused on its core Sportech, industry and services business.

### **Christophe Carniel, Co-Founder and Chief Executive Officer of VOGO, said:**

*"Our inclusion in this consortium is a clear recognition of our technological expertise, our capacity for innovation and our teams' agility. We are equipped to contribute to this strategic project while also staying the course in terms of our R&D roadmap for our core business. Making this test widely available would be a major step towards returning to normal life where sports and cultural events with large crowds, which are impossible today, could resume. This is a defining moment for our industry and our company."*

<sup>(1)</sup> <http://www.cnrs.fr/en/covid-19-clinical-trial-launched-rapid-saliva-based-screening-test>

# Press release

Montpellier, April 14, 2020



## About VOGO

VOGO develops, markets and distributes live & replay, audio and video solutions for spectators and professionals in sports arenas. VOGO's disruptive solution for spectators transforms the stadium experience by providing multi-camera content on demand for viewing on tablets and smartphones, irrespective of the number of people connected. In the professional sphere, VOGO's video solution provides analytical and decision-making tools (referee assistance, medical diagnostics, coaching, etc.). The acquisition of Vokkero® in October 2019 enriched this range of professional solutions, with the integration of an internationally recognised line of audio communications systems. All of the Group's technologies have patent protection. They have already been implemented across more than 20 different sport disciplines. VOGO is present in France (Montpellier and Crolles) and in North America, with an office in New York. The Group has been listed on the Euronext Growth Paris stock market since November 2018 (ISIN code: FR0011532225 – ALVGO).

For more information: [www.vogo-group.com](http://www.vogo-group.com)



[vogo-group.com](http://vogo-group.com)



[vogo](https://twitter.com/vogo)



[vogo](https://www.facebook.com/vogo)

## Contacts

VOGO

Christelle Albinet

Tel: +33(4) 67 50 03 98

Email: [c.albinet@VOGO.fr](mailto:c.albinet@VOGO.fr)

ACTIFIN – Press Relations

Jennifer Julia

Tel: +33(1) 56 88 11 19

Email: [jjulia@actifin.fr](mailto:jjulia@actifin.fr)

ACTIFIN - Financial Communications

Victoire Demeestère / Stéphane Ruiz

Tel: +33(1) 56 88 11 11

Email: [demeestere@actifin.fr](mailto:demeestere@actifin.fr)